Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genprex, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage gene therapy company with common stock traded on The Nasdaq Capital Market under GNPX. The company’s 8-K reports record material-event disclosures on Reqorsa patent grants and patent-application actions, research agreements, investor presentations, preclinical and clinical data presentations, diabetes gene therapy updates, and Nasdaq listing-compliance matters.
Proxy materials provide governance and compensation disclosures, including director and executive compensation tables, pay-versus-performance information and annual meeting matters. The filing record also ties Genprex’s capital-market status to its common stock listing, minimum stockholders’ equity compliance, and Regulation FD treatment for furnished presentation materials and press-release exhibits.
Genprex announced positive preclinical research results for GPX-002, its diabetes gene therapy drug candidate, presented at the 2025 American Diabetes Association Scientific Sessions. The research demonstrated significant breakthroughs in treating Type 1 diabetes using gene therapy.
Key findings include:
- Successfully converted alpha cells into insulin-secreting beta-like cells in animal models, maintaining improved glucose control for three months
- Utilized rAAV delivery system through pancreatic duct infusion to deliver Pdx1 and MafA genes
- Non-human primates showed improved glucose tolerance and reduced insulin requirements one month post-treatment
- Temporary immunosuppression using rituximab, rapamycin, and steroids proved effective for 3 months, with ongoing studies evaluating 6-month protocols
The research suggests GPX-002 could potentially revolutionize diabetes treatment through cell transdifferentiation, though continued studies are needed to optimize immunosuppression protocols and evaluate long-term efficacy in both Type 1 and Type 2 diabetes models.
Genprex announced positive preclinical data for GPX-002, its diabetes gene therapy candidate, presented at the 2025 ADA Scientific Sessions. The research showcased a novel non-viral delivery approach using lipid nanoparticles (LNPs), marking a significant advancement in diabetes treatment technology.
Key findings include:
- Successful testing of 9 LNPs with patented LipexSil® lipids, demonstrating efficient cell transfection in mouse Islets of Langerhans
- ALX-184 LNP showed particular promise in crossing the pancreatic membrane and effectively delivering mRNA payloads
- The non-viral delivery system potentially enables repeat dosing without immunosuppression, a significant advantage over traditional AAV delivery methods
This research runs parallel to Genprex's ongoing AAV construct studies, representing a strategic expansion of their diabetes program. The company believes these findings provide crucial proof of concept for advancing their Type 1 diabetes treatment approach, though they caution that all forward-looking statements are subject to risks and uncertainties.